Mer­ck de­tails PhII TIG­IT/PD-1 fail in lung can­cer

Nine months af­ter re­veal­ing that its TIG­IT/PD-1 com­bo failed a mid-stage lung can­cer study, Mer­ck is spelling out the full re­sults — with the com­bo miss­ing all the pri­ma­ry and sec­ondary end­points.

De­spite the flop, Mer­ck kept go­ing with a slate of Phase III stud­ies it had al­ready launched for the can­di­date, a co­for­mu­la­tion of vi­bostolimab — Mer­ck’s TIG­IT an­ti­body — and its star check­point drug Keytru­da. The first read­out for these stud­ies is ex­pect­ed to ar­rive in 2025, and the com­pa­ny said the da­ta from the Phase II KeyVibe-002 tri­al will in­form the pro­gram.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.